Skip to main content

Table 1 Demographic characteristics in 142 acute febrile prostatic infections

From: Acute bacterial prostatitis and abscess formation

  With abscess (n = 31) Without abscess (n = 111) Statistical results
Underlying factors    
 Age (years)† 62.23 ± 14.60 63.99 ± 14.27 0.546, 2.913, −7.524 ~ 3.994
 BMI (Kg/m2)† 23.93 ± 4.04 24.05 ± 3.79 0.887, 0.827, −1.756 ~ 1.521
 PSA (ng/ml)† 15.95 ± 11.46 20.76 ± 19.17 0.200, 3.730, −12.181 ~ 2.571
 Prostate size (cc)† 47.73 ± 19.25 40.80 ± 17.53 0.063, 3.694, −0.377 ~ 14.242
 Abscess size (mm) 22.03 ± 11.69 NA
<10 mm: 4; 10 ~ 20 mm: 12; 20 ~ 30 mm: 8; >30 mm: 7
 Other abscess foci 4; 2 liver abscesses, 1 renal abscess, 1 buttock abscess 2; 1 liver abscess, 1 renal abscess NA
 Symptom duration† 7.81 ± 5.42 3.04 ± 2.57 <0.001, 0.691, 3.404 ~ 6.136
Underlying diseases    
 Diabetes mellitus‡ 16/31 32/111 0.030, 2.633, 1.165 ~ 5.951
 Hypertension‡ 11/31 49/111 0.418, 0.696, 0.305 ~ 1.589
 Heart disease‡ 4/31 23/104 0.316, 0.522, 0.166 ~ 1.644
 Neurological deficit‡ 10/31 31/111 0.658, 1.229, 0.520 ~ 2.903
 Chronic kidney disease* 4/31 16/111 1.000, 0.880, 0.271 ~ 2.851
 Chronic lung disease* 2/31 11/111 0.734, 0.627, 0.131 ~ 2.991
 Liver cirrhosis* 7/31 15/111 0.261, 1.867, 0.685 ~ 5.087
 Previous hospitalizations‡ 8/31 16/111 0.174, 2.065, 0.788 ~ 5.411
 Urological procedures* 3/31
3 cystoscopy
10/111
4 cystoscopy
4 prostate biopsy
2 urodynamic study
1.000, 1.082, 0.279 ~ 4.201
0.176, 2.866, 0.606 ~ 13.553
NA
NA
 Long term catheterization* 2/31 12/111 0.735, 0.569, 0.120 ~ 2.689
 Recent catheterization* 5/31 8/111 0.158, 2.476, 0.748 ~ 8.198
 Voiding disturbance (Qmax < 5 or PVR > 100)‡ 15/31 15/111 <0.001, 6.000, 2.464 ~ 14.612
Treatment outcomes    
 Septic shock* 3/31 3/111 0.118, 3.857, 0.738 ~ 20.152
 Death 1/31 1/111 0.390, 3.667, 0.223 ~ 60.360
 Recurrence 1/31 3/111 1.000, 1.189, 0.119 ~ 11.848
 Treatment duration† 40.96 ± 10.61 26.98 ± 9.43 <0.001, 2.111, 9.802 ~ 18.158
 With TUR-P (n = 13)a 32.31 ± 9.34   0.001††
 Without TUR-P (n = 13)b 40.85 ± 7.94  
 Admission duration† 12.38 ± 6.59 6.69 ± 2.92 <0.001, 1.321, 2.978 ~ 8.403
 With TUR-P (n = 13)a 10.23 ± 2.55   0.650††
 Without TUR-P (n = 13)b 11.08 ± 9.32  
 Follow-up duration† 216.0 ± 69.92 202.11 ± 59.01 0.302, 13.391, −12.602 ~ 40.378
  1. †: These continuous values are expressed as means ± standard deviations and student t-tests were performed (statistical data include p-values, standard errors and 95 % confidence intervals, respectively)
  2. ‡,*: Statistical evaluation for the nominal parameters was performed using the Chi-squared test‡ or Fisher’s exact test* (statistical data include p-values, odds ratios and 95 % confidence intervals, respectively.)
  3. ††: p-values between ‘a’ and ‘b’ were evaluated using the Mann–Whitney U test. Note that all cases (n = 13) treated by TUR-P had abscesses >20 mm in size
  4. Among the 142 cases, 6 cases with metastatic abscesses (1 patient underwent TUR-P) and 2 fatal cases were excluded when comparing the treatment duration, admission duration and follow-up duration
  5. Abbreviations: BMI body mass index; PSA prostate specific antigen; Qmax (ml/sec) maximum urinary flow rate; PVR (ml) post-void residual; TUR-P transurethral resection of prostate